Vaccine Development

Plexus acquires exclusive position for demographically targeted T-cell vaccine discovery

Published in Hepatitis Weekly, July 22nd, 2002

Plexus Vaccine, Inc., a San Diego based biotechnology company employing rational drug design principles for vaccine discovery and development, announces that it has established a Danish subsidiary under the name Plexus Denmark Aps.

The Danish subsidiary will assist Plexus in developing new vaccines based on a combination of advanced computational and experimental biochemical methods.

Through a license agreement with the Danish scientists Professor Soeren Brunak and Professor Soeren Buus, Plexus has secured exclusive access to technology that will constitute a cornerstone in the activities of Plexus Denmark and significantly strengthen the overall...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-07-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry